Teva to coparttate with the Technion and promote innovative R&D in the fields of cancer and the brain

Teva continues its strategic collaborations with academic institutions in Israel. Teva has signed an agreement with the Technion to promote innovative research and development in the fields of cancer and the brain. The agreement with the Technion was subsequently signed for the strategic collaborations created by Teva with the Weizmann Institute of Science and Tel Aviv University.
In recent months, collaborations have been signed between Teva and the Technion in the field of immunotherapy for cancer and nervous system diseases. This is also in the shadow of the corona crisis, when in recent months the joint research has gained momentum, and the researchers at the Technion are working to promote research with the help of research and development groups of nature from Israel and the world. The new projects that have been signed recently focus on developing new immunotherapy methods in the fields of cancer and the brain.
Currency research teams and the Technion are conducting a joint study to test the effectiveness of innovative immunotherapy treatments with antibodies, or cell therapy in unique models for the treatment of cancer, Parkinson's and migraine. For example, the projects combine advanced technologies to develop smart drug carriers that can reach the brain or cancerous tumors, activate relevant areas of activity in the brain and examine their effect on the nervous periphery and immune system, and study the effect of microbiome on the development of Parkinson's disease.